Antibody responses to meningococcal polysaccharide vaccine in adults without a spleen

Ruben, Frederick L.; Hankins, William A.; Zeigler, Zella R.; Norden, Carl W.; Harrison, Annie; Winkelstein, Alan; Herrmann, Diane J.

doi:10.1016/0002-9343(84)90759-9

Cited by 47 publications

(12 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some guidelines have also recommend that the asplenic individual receive the conjugated Hemophilus and meningococcal vaccines [5,18,23,24]. Vaccination should never result in a false sense of security since sporadic cases of pneumococcal and other vaccine failures have been reported in appropriately immunized persons, some of whom have also been taking prophylactic antibiotics [9,10,22,25].…”

Section: Discussionmentioning

confidence: 99%

Pneumococcal vaccine administration associated with splenectomy: The need for improved education, documentation, and the use of a practical checklist

2000

View full text Add to dashboard Cite

An audit was performed of the documentation of pneumococcal vaccination in splenectomy patients in three major hospitals involving a geographical population base of 350,000 patients in British Columbia, Canada. Overall, 111 of the 164 hospitalized splenectomy patients (68%) had received pneumococcal vaccination. Of elective splenectomy cases, only 11 of 55 (20%) had been vaccinated prior to surgery, as is currently recommended. One hundred fifty-five patients (95%) had splenectomy status mentioned in the discharge summary. However, only 35 (21%) had mention of vaccination status, 10 (6%) mention of the need for future revaccination, and only 8 (5%) notation of the possibility of future infectious risks. The rate of pneumococcal vaccination was as satisfactory as any reported in the literature to date. However, there is need for improved education in relation to the timing of vaccination and discharge summary documentation. A checklist for potential splenectomy patients may aid in improving this situation as may geographically based splenectomy registries.

show abstract

Section: Discussionmentioning

confidence: 99%

Pneumococcal vaccine administration associated with splenectomy: The need for improved education, documentation, and the use of a practical checklist

2000

View full text Add to dashboard Cite

show abstract

“…The immunogenicity of the serogroup W-135 and Y components has been demonstrated when given alone, combined, and together with the A and C components as a tetravalent vaccine (6,11,50,155,156,206,368). MPSV4 is immunogenic in anatomically asplenic persons whose spleens were removed because of nonlymphoid tumors or trauma (243,302). In persons with terminal complement deficiency, the vaccine is immunogenic and appears to provide some clinical protection, presumably by opsonic antibodies (91,271).…”

Section: Meningococcal Vaccines Polysaccharide Vaccinesmentioning

confidence: 99%

Prospects for Vaccine Prevention of Meningococcal Infection

2006

View full text Add to dashboard Cite

SUMMARY Neisseria meningitidis is the leading cause of bacterial meningitis in the United States and worldwide. A serogroup A/C/W-135/Y polysaccharide meningococcal vaccine has been licensed in the United States since 1981 but has not been used universally outside of the military. On 14 January 2005, a polysaccharide conjugate vaccine that covers meningococcal serogroups A, C, W-135, and Y was licensed in the United States for 11- to 55-year-olds and is now recommended for the routine immunization of adolescents and other high-risk groups. This review covers the changing epidemiology of meningococcal disease in the United States, issues related to vaccine prevention, and recommendations on the use of the new vaccine.

show abstract

“…Most centers also recommend vaccination against H. influenzae type b, N. meningitidis serogroups A and C and influenza. Asplenic patients without underlying disease have been shown to achieve protective antibody levels when immunized with the current Hib conjugate vaccine [42] and obtain similar responses to healthy individuals with the current bivalent meningococcal vaccine (A and C) [43]. Type B meningococcus, which causes the majority of invasive disease, is not covered by the current vaccine owing to the reduced immunogenicity of the type B polysaccharide [43].…”

Section: Commentsmentioning

confidence: 99%